• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hematology: Bortezomib and dexamethasone induction for multiple myeloma.

作者信息

Laubach Jacob, Richardson Paul

出版信息

Nat Rev Clin Oncol. 2011 Jan;8(1):8-10. doi: 10.1038/nrclinonc.2010.206.

DOI:10.1038/nrclinonc.2010.206
PMID:21179054
Abstract
摘要

相似文献

1
Hematology: Bortezomib and dexamethasone induction for multiple myeloma.血液学：硼替佐米与地塞米松用于多发性骨髓瘤的诱导治疗。
Nat Rev Clin Oncol. 2011 Jan;8(1):8-10. doi: 10.1038/nrclinonc.2010.206.
2
Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy.硼替佐米、环磷酰胺和地塞米松：对快速逆转骨髓瘤相关的高氨血症性脑病非常有效。
Leuk Lymphoma. 2010 Dec;51(12):2299-302. doi: 10.3109/10428194.2010.518654. Epub 2010 Oct 7.
3
A new standard of care in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤的一种新护理标准。
Lancet. 2010 Dec 18;376(9758):2043-4. doi: 10.1016/S0140-6736(10)62177-0. Epub 2010 Dec 9.
4
[Carfilzomib in multiple myeloma relapses].[卡非佐米用于多发性骨髓瘤复发治疗]
Bull Cancer. 2015 Feb;102(2):116.
5
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.硼替佐米为基础与非硼替佐米为基础的诱导治疗在前未经治疗多发性骨髓瘤患者自体造血干细胞移植前：III 期随机对照试验的荟萃分析。
J Clin Oncol. 2013 Sep 10;31(26):3279-87. doi: 10.1200/JCO.2012.48.4626. Epub 2013 Jul 29.
6
Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.硼替佐米、沙利度胺和地塞米松联合治疗复发难治性IgD型多发性骨髓瘤
Leuk Lymphoma. 2005 Apr;46(4):567-9. doi: 10.1080/10428190400029700.
7
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.硼替佐米-环磷酰胺-地塞米松（VCD）与硼替佐米-沙利度胺-地塞米松（VTD）方案作为新诊断的适合移植的多发性骨髓瘤患者诱导治疗的比较：一项荟萃分析
Br J Haematol. 2014 Sep;166(5):702-10. doi: 10.1111/bjh.12946. Epub 2014 May 26.
8
[About treatment of multiple myelomas. A report at the 10th International Workshop in Sydney].[关于多发性骨髓瘤的治疗。在悉尼举行的第十届国际研讨会上的一份报告]
Recenti Prog Med. 2005 Jul-Aug;96(7-8):405-9.
9
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.硼替佐米联合沙利度胺-地塞米松用于既往未经治疗的多发性骨髓瘤
Hematology. 2007 Jun;12(3):235-9. doi: 10.1080/10245330701214236.
10
Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib.一名多发性骨髓瘤患者的硬化性黏液水肿和皮肤-神经综合征经地塞米松和硼替佐米有效治疗。
Am J Hematol. 2011 Oct;86(10):893-6. doi: 10.1002/ajh.22131.

引用本文的文献

1
The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.新型药物的使用可有效提高肾功能损害的多发性骨髓瘤患者的缓解率、延缓复发并提高总生存率。
PLoS One. 2014 Jul 8;9(7):e101819. doi: 10.1371/journal.pone.0101819. eCollection 2014.
2
Hematology in 2010: New therapies and standard of care in oncology.2010 年血液学：肿瘤学中的新疗法和标准治疗。
Nat Rev Clin Oncol. 2011 Feb;8(2):67-8. doi: 10.1038/nrclinonc.2010.221.

本文引用的文献

1
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.硼替佐米和长春新碱相关的多发性骨髓瘤患者周围神经病的发病机制：HOVON-65/GMMG-HD4 试验前瞻性数据分析。
Lancet Oncol. 2010 Nov;11(11):1057-65. doi: 10.1016/S1470-2045(10)70206-0. Epub 2010 Sep 21.
2
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.硼替佐米联合地塞米松优于长春新碱联合多柔比星联合地塞米松作为新诊断多发性骨髓瘤患者自体造血干细胞移植前的诱导治疗：IFM 2005-01 期 III 期试验结果。
J Clin Oncol. 2010 Oct 20;28(30):4621-9. doi: 10.1200/JCO.2009.27.9158. Epub 2010 Sep 7.
3
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.来那度胺、硼替佐米和地塞米松联合治疗新诊断的多发性骨髓瘤患者。
Blood. 2010 Aug 5;116(5):679-86. doi: 10.1182/blood-2010-02-268862. Epub 2010 Apr 12.
4
CR represents an early index of potential long survival in multiple myeloma.CR 代表多发性骨髓瘤潜在长期生存的早期指标。
Bone Marrow Transplant. 2010 Mar;45(3):498-504. doi: 10.1038/bmt.2009.176. Epub 2009 Jul 27.
5
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.移植前后反应对多发性骨髓瘤患者预后的影响：反应的序贯改善和完全缓解的实现与更长的生存期相关。
J Clin Oncol. 2008 Dec 10;26(35):5775-82. doi: 10.1200/JCO.2008.17.9721. Epub 2008 Nov 10.
6
Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.接受自体干细胞移植的骨髓瘤患者生存的预测因素：211例患者的单中心经验
Bone Marrow Transplant. 2006 Apr;37(8):731-7. doi: 10.1038/sj.bmt.1705307.
7
Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.多发性骨髓瘤的自体移植：意大利骨髓移植研究组对290例患者的回顾性分析
Haematologica. 1999 Sep;84(9):844-52.